Black Diamond Therapeutics Inc shares doubled after it saw positive initial dose escalation data from a study demonstrating the anti-tumor activity of BDTX-1535 in non-small cell lung (NSCL) cancer patients.
The new data from the dose escalation portion of the Phase 1 study demonstrated clinical proof of activity of BDTX-1535 in NSCL cancer patients with both acquired resistance and intrinsic driver epidermal growth factor receptor (EGFR) mutations.
Investors reacted to the news, sending the company’s shares up over 108% to $3.83 in morning trade.
“These initial safety and clinical activity data support the continued development of BDTX-1535 as a potential first and best-in-class treatment option for osimertinib-resistant NSCLC patients,” Black Diamond chief medical officer Sergey Yurasov said in a statement.
“Importantly, BDTX-1535 is the first EGFR TKI to show radiographic responses across NSCLC patients whose cancers are driven by diverse mutation families including acquired resistance mutations after osimertinib therapy, as well as in patients whose cancers are driven by classical and intrinsic driver mutations, providing clinical validation for our MasterKey approach of targeting families of mutations with a single drug,” he added.
BDTX-1535 is an investigational fourth-generation epidermal growth factor receptor MasterKey inhibitor being developed for the treatment of non-small cell lung cancer and glioblastoma multiforme.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive